APA (7th ed.) Citation

Chen, G., Sun, D., Ba, Y., Zhang, Y., Zhou, T., Zhao, Y., . . . Yang, Y. (2025). Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: An open-label, multicenter, phase Ib/II trial. Journal of hematology and oncology, 18(1), 15-10. https://doi.org/10.1186/s13045-025-01666-6

Chicago Style (17th ed.) Citation

Chen, Gang, et al. "Anti-LAG-3 Antibody LBL-007 Plus Anti-PD-1 Antibody Toripalimab in Advanced Nasopharyngeal Carcinoma and Other Solid Tumors: An Open-label, Multicenter, Phase Ib/II Trial." Journal of Hematology and Oncology 18, no. 1 (2025): 15-10. https://doi.org/10.1186/s13045-025-01666-6.

MLA (9th ed.) Citation

Chen, Gang, et al. "Anti-LAG-3 Antibody LBL-007 Plus Anti-PD-1 Antibody Toripalimab in Advanced Nasopharyngeal Carcinoma and Other Solid Tumors: An Open-label, Multicenter, Phase Ib/II Trial." Journal of Hematology and Oncology, vol. 18, no. 1, 2025, pp. 15-10, https://doi.org/10.1186/s13045-025-01666-6.